v3.26.1
Collaboration, License and Option Agreements - Gilead Sciences, Inc. (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2024
USD ($)
Item
$ / shares
shares
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Agreements            
Revenue   $ 18,692 $ 8,084 $ 31,340 $ 11,014  
Revenue from Contract with Customer, Product and Service   Collaboration And License Member Collaboration And License Member Collaboration And License Member Collaboration And License Member  
Deferred revenue   $ 35,318   $ 35,318   $ 60,658
Deferred revenue, current portion   22,603   22,603   40,023
License and Stock Purchase Agreement | Gilead Sciences, Inc.            
Agreements            
Maximum additional contingent payments receivable, Transition fee $ 75,000     75,000    
Gross proceeds from issuance of private placement $ 25,000     25,000    
Development milestone payment received from Gilead       17,500    
Number of private placements | Item 3          
Common stock and prefunded warrants purchased (in shares) | shares 650,387          
Maximum beneficial ownership (as a percent) 19.90%          
Upfront payment       72,500    
Upfront payment, cash       30,000    
Maximum additional contingent payments receivable       575,000    
Maximum additional contingent payments receivable, Milestones       500,000    
Maximum additional contingent payments receivable, Near-term development milestones           17,500
Fair market value of common stock issued (in dollars) $ 4,400          
Premium of common stock issued (in dollars) $ 9,100          
Number of promises | Item 2          
Transaction price $ 39,100          
Transaction price, Cash payment 30,000          
Transaction price, Premium on sale of stock $ 9,100          
Revenue   6,000 $ 3,300 10,600 $ 5,500  
Deferred revenue   16,037   16,037   $ 26,651
Deferred revenue, current portion   $ 13,200   $ 13,200    
License and Stock Purchase Agreement | Gilead Sciences, Inc. | Prefunded warrants            
Agreements            
Number of common stock into which the class of warrant or right purchased may be converted | shares 712,514          
Exercise price, warrants (in dollars per share) | $ / shares $ 0.0014